Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion [6][42] - Adjusted earnings per diluted share was $33.05, exceeding expectations with a year-over-year growth of 20% [6][45] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth [35][36] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment revenues increased 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty products [36] - The Prescription Technology Solutions segment saw revenues increase 13% to $1.3 billion, with operating profit rising 34% to $285 million [37] - The Medical Surgical Solutions segment revenues increased 1% to $2.9 billion, with operating profit up 15% to $285 million [39] Market Data and Key Metrics Changes - Revenues from GLP-1 medications in the fourth quarter were $10.9 billion, a 46% increase compared to the prior year [36] - The Canadian business, part of the international segment, experienced a 2% revenue decrease due to divestitures, but operating profit increased 9% [40][60] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of Prism Vision and Core Ventures [7][12] - A decision was announced to separate the Medical Surgical segment into an independent company to enhance strategic focus and capital deployment [20][29] - The company aims to leverage technology, automation, and AI to improve operational efficiencies and enhance financial profiles [9][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to continue momentum and deliver strong results in fiscal 2026, anticipating revenue growth of 11% to 15% [46][66] - The company is closely monitoring the macroeconomic environment and potential impacts from policy changes, but remains optimistic about the healthcare industry's resilience [26][100] - Management emphasized the importance of community-based care and its role in managing healthcare costs and accessibility [72] Other Important Information - The company returned $3.5 billion to shareholders, including $3.1 billion through share repurchases [45] - Free cash flow for the fiscal year was $5.2 billion, driven by strong operational results [45][41] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no confirmed changes and emphasized the importance of community-based care in managing costs [69][72] Question: Tariff Impacts on Business - Management is monitoring the tariff landscape but does not anticipate a material impact on fiscal 2026 guidance [78][85] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [90][93] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in guidance reflects a stable environment for prescription utilization and successful capital deployment [97][101] Question: SG&A Efficiency Improvements - Management acknowledged a substantial decline in SG&A expenses year-over-year, attributing it to operational efficiencies [105]

Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion, with adjusted earnings per diluted share at $33.5, exceeding expectations and reflecting a year-over-year EPS growth of 20% [5][40][42] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth across the business [32][29] - Operating profit for the full year increased 15% to $5.6 billion, with significant contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments [41][42] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment saw revenues increase by 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty product distribution [33][22] - The Prescription Technology Solutions segment reported a revenue increase of 13% to $1.3 billion, with operating profit rising 34% to $285 million, reflecting increased prescription transaction volumes [34][35] - The Medical Surgical Solutions segment experienced a 1% revenue increase to $2.9 billion, with operating profit up 15% to $285 million, benefiting from cost optimization initiatives [37][36] Market Data and Key Metrics Changes - The Canadian business, part of the international segment, reported revenues of $3.5 billion, a decrease of 2% due to the divestiture of certain businesses, but operating profit increased by 9% [38][24] - The company anticipates continued growth in the Canadian distribution business, partially offset by the impact of previous divestitures [58] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of a controlling interest in Prism Vision and Core Ventures, aimed at enhancing community-based care [6][12][49] - A strategic decision was made to separate the Medical Surgical segment into an independent company to enhance operational focus and capital deployment [19][27] - The company plans to continue investing in technology, automation, and AI to improve operational efficiencies and customer service [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to maintain momentum and deliver strong results in fiscal 2026, with anticipated revenue growth of 11% to 15% and operating profit growth of 8% to 12% [43][44] - The company remains committed to maximizing shareholder value through disciplined portfolio management and strategic capital deployment [27][62] Other Important Information - The company returned $3.5 billion to shareholders in fiscal 2025, including $3.1 billion through share repurchases [42] - Free cash flow for the fourth quarter was robust at $7.5 billion, driven by strong operating results [39] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no concrete announcements regarding Medicare Part B impacts, and any potential changes would likely face legal challenges [65][66] Question: Tariff Impacts on Business - Management is closely monitoring the tariff landscape and believes that current assessments have been incorporated into guidance, with no material impact anticipated on fiscal 2026 results [75][81] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [85][88] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in long-term guidance reflects a stable environment for prescription utilization and successful capital deployment in oncology and other specialties [92][96]

McKesson Corporation Fiscal 2025 Financial Results Fiscal 2026 Outlook May 8, 2025 Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approximately," "intends," "projects," "plans," "estimat ...

Core Insights - Wellgistics Health, Inc. is launching an initiative to utilize XRP as a treasury reserve and real-time payments infrastructure, aiming to be among the first publicly traded healthcare companies to do so [1][3] - The initiative is backed by a $50 million Equity Line of Credit (ELOC) to enhance liquidity and financial infrastructure within its healthcare network [2] Company Strategy - The company aims to disrupt traditional healthcare systems by connecting manufacturers directly to pharmacies and patients, thereby increasing speed, liquidity, and transparency [3] - Wellgistics Health believes that the future of healthcare will favor companies with efficient platforms rather than those with large physical infrastructures [3] XRP Integration Benefits - The integration of XRP is expected to facilitate faster vendor payments, performance-based rebates, and liquidity tools for pharmacies and manufacturers [4] - XRP transactions settle in 3-5 seconds, significantly faster than traditional methods, and cost less than $0.0002 per transfer, compared to $10-$30 for standard bank wires [7] Market Trends - XRP is gaining traction among global institutions, with CME Group set to launch cash-settled XRP futures in May 2025 to meet institutional demand [6] - Mastercard has identified XRP as a bridge currency for cross-border payments, highlighting its efficiency and cost-effectiveness [7] Company Overview - Wellgistics Health operates across pharmaceutical distribution, prescription technology, and clinical fulfillment, connecting over 150 manufacturers to more than 6,000 independent pharmacies [9] - The company provides real-time prescription hub services and aims to eliminate friction in the supply chain, enhancing reimbursement processes and creating transparent pathways [10]

Core Insights - Wellgistics Health, Inc. is launching an initiative to utilize XRP as a treasury reserve and real-time payments infrastructure, aiming to be among the first publicly traded healthcare companies to do so [1][3] - The initiative is backed by a $50 million Equity Line of Credit (ELOC) to enhance liquidity and financial infrastructure across its healthcare network [2] Company Strategy - The company aims to disrupt traditional healthcare systems by connecting manufacturers directly to pharmacies and patients, thereby increasing speed, liquidity, and transparency [3] - Wellgistics Health believes that the future of healthcare will favor companies with efficient platforms rather than those with large physical infrastructures [3] XRP Integration Benefits - The integration of XRP is expected to facilitate faster vendor payments, performance-based rebates, and liquidity tools for pharmacies and manufacturers [4] - XRP transactions settle in 3-5 seconds, significantly faster than traditional methods, and cost less than $0.0002 per transfer, enhancing operational efficiency [7] Market Positioning - Wellgistics Health is positioning itself to lead in the healthcare and fintech convergence by leveraging XRP, as evidenced by the growing institutional interest in XRP [6][8] - The company is focused on unlocking capital velocity and running operations more efficiently than its peers in the pharmaceutical infrastructure space [6] Industry Trends - XRP is gaining traction with major institutions, including the CME Group launching XRP futures and Mastercard identifying XRP as a bridge currency for cross-border payments [6][7] - Ripple's recent acquisitions and regulatory advancements further solidify XRP's role in the financial services landscape [8] Company Overview - Wellgistics Health operates in pharmaceutical distribution, prescription technology, and clinical fulfillment, connecting over 150 manufacturers to more than 6,000 independent pharmacies [9] - The company provides real-time prescription services and aims to streamline the medication supply chain by reducing friction and accelerating reimbursements [10]

Core Viewpoint - Cencora (COR) is expected to report second-quarter fiscal 2025 results on May 7, with anticipated revenue of $74.82 billion, reflecting a 9.4% year-over-year increase, and earnings per share of $4.08, indicating a 7.4% improvement from the prior year [1][2] Group 1: Financial Performance - Cencora's U.S. Healthcare Solutions segment is projected to have achieved 14% revenue growth to $74 billion and a 10% increase in segment operating income, driven by strong demand for specialty distribution and GLP-1 drugs [2][3] - The company is expected to report revenues of $66.61 billion for the GLP-1 drug segment, with adjusted operating income estimated at $901.9 million [4][7] - The international Healthcare Solutions segment is anticipated to show 5.5% revenue growth, but a 3% decrease in reported operating income, primarily due to a stronger U.S. dollar affecting reported growth [5] Group 2: Market Dynamics - Cencora's strong distribution execution and the growing adoption of biosimilars position the company for consistent revenue performance [3] - The company faces challenges from declining COVID-19 vaccine contributions, which may negatively impact segment sales and margins [4] - A continuation of softer performance in specialty logistics, particularly World Courier, is expected due to muted activity in clinical trials and cell and gene therapies [6] Group 3: Earnings Expectations - The model predicts an earnings beat for Cencora, supported by a positive Earnings ESP of +0.82% and a Zacks Rank of 2 (Buy) [8][9]

Financial Data and Key Metrics Changes - The company reported operating earnings growth of 21% and EPS growth of 13%, with EPS for the quarter at $2.35 [12][14] - Total company revenue was flat at nearly $55 billion, but adjusted for contract expiration, revenue increased by 19% year-over-year [13] - Total company gross profit dollars increased by 10%, while SG&A increased by only 4%, indicating strong cost control [13][14] Business Line Data and Key Metrics Changes - Pharmaceutical and Specialty Solutions revenue was relatively flat at $50.4 billion, but excluding customer contract expiration, revenue increased by 20% [15] - GNPD segment revenue increased by 2% to $3.2 billion, driven by volume growth from existing customers [17] - Other businesses reported a 13% revenue increase to $1.3 billion, with profit growth across all three operating segments [18] Market Data and Key Metrics Changes - The company generated over 99% of its enterprise revenue in the U.S., with 95% of segment profit from four of its five businesses largely unaffected by tariffs [9] - The company expects fiscal year 2025 revenue growth of 17% to 19% and segment profit growth of 16% to 18% in its Other segment [25] Company Strategy and Development Direction - The company has invested approximately $7 billion in the U.S. over the last two years, focusing on acquisitions, domestic manufacturing, and technology [9] - The company is committed to increasing patient access, affordability, and innovation in healthcare while navigating regulatory complexities [9][10] - The addition of Advanced Diabetes Supply Group is expected to be accretive to EPS and enhance the company's capabilities in diabetes care [11][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to generate sustainable long-term growth, raising fiscal year 2025 EPS guidance to a range of $8.5 to $8.15 [11][21] - The company anticipates continued strong demand and organic growth fueled by favorable market trends and competitive positioning [27] - Management is focused on mitigating tariff impacts through operational improvements and pricing strategies [36][66] Other Important Information - The company has completed customer onboardings that contribute approximately $10 billion of new customer revenue in fiscal year 2025 [23] - The effective tax rate for Q3 was 22.4%, a 2.5% increase from the prior year [14] Q&A Session Summary Question: Can you discuss the strong brand and specialty sales growth? - Management noted broad-based strength across various categories, with specialty distribution growth in the mid-teens and contributions from new customers [44][45] Question: Are there any headwinds from consumer weakness related to tariffs? - Management indicated no significant changes in demand, emphasizing the resilience of pharmaceutical demand even during macroeconomic challenges [53][54] Question: What is the AOI percentage for Cardinal Health brand revenue? - Approximately $4 billion of GNPD revenue comes from Cardinal Health brand, which has seen good volume growth [61] Question: How will the company offset tariff exposure? - Management stated that the majority of the anticipated $200 to $300 million in tariff costs will be addressed through pricing adjustments and operational actions [66][67] Question: What is the outlook for fiscal year 2026? - Management expects double-digit EPS growth, primarily driven by the Pharma segment, despite potential macro challenges [110]

Financial Data and Key Metrics Changes - The company reported operating earnings growth of 21% and EPS growth of 13%, with EPS for the quarter at $2.35 [11][12] - Total company revenue was flat at nearly $55 billion, but adjusted for contract expiration, revenue increased by 19% year-over-year [12][21] - Total company gross profit dollars increased by 10%, while SG&A increased by only 4%, indicating strong cost control [12][13] Business Line Data and Key Metrics Changes - Pharmaceutical and Specialty Solutions revenue was relatively flat at $50.4 billion, but excluding customer contract expiration, revenue increased by 20% [14][15] - GNPD segment revenue increased by 2% to $3.2 billion, driven by volume growth from existing customers [16] - Other businesses reported a 13% revenue increase to $1.3 billion, with At Home Solutions growing by 12%, Optifreight Logistics by 17%, and Nuclear by 14% [18] Market Data and Key Metrics Changes - The company generated over 99% of its enterprise revenue in the U.S., with 95% of segment profit from four of its five businesses largely unaffected by tariffs [6][7] - The company expects fiscal year 2025 revenue growth of 17% to 19% and segment profit growth of 16% to 18% in its Other segment [24] Company Strategy and Development Direction - The company has invested approximately $7 billion in the U.S. over the last two years, focusing on acquisitions, domestic manufacturing, and technology [7] - The company aims to enhance patient access, affordability, and innovation in healthcare while navigating regulatory complexities [6][7] - The addition of Advanced Diabetes Supply Group is expected to be accretive to EPS and enhance the company's capabilities in diabetes care [10][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to generate sustainable long-term growth and raised fiscal year 2025 EPS guidance to a range of $8.5 to $8.15 [10][21] - The company anticipates continued strong demand and organic growth driven by favorable market trends and competitive positioning [27][29] - Management acknowledged potential challenges from tariffs but emphasized proactive measures to mitigate impacts on customers and operations [35][36] Other Important Information - The company completed the acquisition of GI Alliance and Integrated Oncology Network, which are performing as expected [9][10] - The company has delivered adjusted free cash flow of $1.2 billion year-to-date and repurchased $750 million in shares [19][20] Q&A Session Summary Question: Strong brand and specialty sales growth - Management noted broad-based strength in brand and specialty sales, driven by multiple categories and new customer onboarding [44][46] Question: Consumer weakness related to tariffs - Management indicated no significant changes in consumer behavior or prescription demand despite macroeconomic concerns [53][54] Question: Cardinal Health brand revenue and USMCA coverage - Approximately $4 billion of GNPD revenue comes from Cardinal Health brand, which is higher margin relative to national brands [59][60] Question: Tariff impact on Cardinal Health brand - The majority of the anticipated $200 to $300 million in tariff costs will be addressed through pricing adjustments, particularly for Cardinal Health brand products [64][66] Question: Margin expansion in pharma - Management attributed margin expansion to growth in specialty and brand drug sales, acquisitions, and effective cost control measures [84][86] Question: Customer onboarding and new customer wins - The onboarding of new customers is progressing well, with a reaffirmation of $10 billion in incremental new customer revenue for the year [95][96]

Q3 FY25 Earnings Cardinal Health, Inc. May 1, 2025 © 2025 Cardinal Health. All Rights Reserved. 1 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings Cautions Concerning Forward-Looking Statements Q3 Results © 2025 Cardinal Health. All Rights Reserved. 3 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These st ...